Product Reports Resources Pricing Login Book a demo

Blueprint Medicines

Biotech & Life Sciences · Cambridge, United States · Founded 2011 · IPO 2015

Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases

Valuation $8.25B
Revenue $509M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue
Knowledge graph
News Ringg lands $10M from Peak XV to expand voice AI beyond calls Aug 26, 2026 Market map billionaire funded longevity startups

Talent graph

Blueprint Medicines's talent

Book a demo to see the people
Employees mapped 712 incl. 5 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 7 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Blueprint Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
F-Prime
Eight Roads Ventures
Third Rock Ventures
Series B+ 4 investors entered at this stage
Nextech Invest
PFM Health Sciences
RA Capital Management
Casdin Capital

Blueprint Medicines mafia

Startups founded by Blueprint Medicines alumni

Former Blueprint Medicines employees who went on to start their own companies. Sorted by Dealroom signal score.

Solve TherapeuticsEst. 2021
Dave JohnsonUnited States
Signal score91
Recludix PharmaEst. 2019
BHBrian HodousUnited States
Signal score71
Nested TherapeuticsEst. 2021
Klaus HoeflichUnited States
Signal score69
Frontier MedicinesEst. 2018
Chris VarmaUnited States
Signal score68
Celsius TherapeuticsEst. 2018
Christoph LengauerUnited States
Signal score63
IDRxEst. 2022
George DemetriUnited States
Signal score63
EQRxEst. 2019
Alexis BorisyUnited States
Signal score61

Book a demo to explore the full alumni network →

Global footprint

Where Blueprint Medicines has talent and traffic

Workforce by country
12 countries with
team presence
🇺🇸 United States85.9%
🇩🇪 Germany4%
🇨🇭 Switzerland3.7%
🇪🇸 Spain1.6%
🇮🇹 Italy1.4%
Top 5 of 12 shown
Web traffic by country
14K monthly visits
across markets
🇺🇸 United States53.6%
🇮🇳 India17.1%
🇪🇸 Spain7.1%
🇨🇦 Canada6.4%
🇫🇷 France5%
Top 5 markets shown

Patent intelligence

$90M patent portfolio · 80 active families

Estimated portfolio value
$90M
1.1% of market cap · 3.7× smaller than top peer Translate Bio ($336M)
80 active patent families
Where Blueprint Medicines innovates BiochemistryCancer researchCarcinosisDiseaseMedicinal chemistry

Where Blueprint Medicines concentrates vs peers

Each axis is a top-10 topic across Blueprint Medicines and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Blueprint Medicines

An AI-synthesized read of the highest-engagement posts about Blueprint Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Blueprint Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles